pCDCAR1 CD19 h(BBζ, α/β/γ)(CAR-LC299)
The vector of anti-CD19 chimeric antigen receptor (CAR) is based on the FcεRI receptor scaffold and constructed for the engineering of T cells to target human CD19. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD19 antibody linked to FcRα, CD137 (4-1BB) signaling domain, FcRβ linked to CD3ζ signaling domain and FcRγ. And the vector product was designed for the treatment of chronic lymphoid leukemia.
Targeting Cell Type
Chronic lymphocytic leukemia
Discription of Signaling Cassetes
CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ , ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T cell surface antigen Leu-12; B-lymphocyte surface antigen B4; Chronic Lymphocytic Leukemia; CLL; scFv; CD28; Leukemia; chimeric T cell receptors; chimeric immunoreceptors; chimeric antigen receptors; FMC63
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
||Lenti-CD19 CAR (scFv-CD28-CD27-FcεRIγ, FMC63) Viral Particle
||Lenti-CD19 CAR (scFv-FcεRIγ, FMC63) Viral Particle
||Anti-CD19 (4G7) h(41BB/CD3ζ) Multi-chain CAR, pCDCAR1
||Anti-CD19 h(CD3ζ, RXR/EcR) Conditional CAR, pCDCAR1
||Lenti-CD19 CAR (scFv-CD3ζ, FMC63) Viral Particle
||Lenti-CD19 CAR (scFv-41BB-CD3ζ, S2) Viral Particle
||Anti-CD19 scFv h(CD3ζ-41BB) CAR, pCDCAR1
||Anti-CD19 (FMC63) h(41BB-CD3ζ,CD20) Self-destruct CAR, pCDCAR1
||Anti-CD19 (Blinatumomab) h(CD28-CD3ζ, EGFRt) Marked CAR, pCDCAR1
||Anti-CD19 (FMC63) h(41BB-CD3ζ, K4/E4) Conditional CAR, pCDCAR1